Imel, E. A., Glorieux, F. H., Whyte, M. P., Munns, C. F., Ward, L., Nilsson, O., . . . Portale, A. A. (2019). Burosumab versus continuation of conventional therapy in children with X-linked hypophosphatemia: A randomised, active-controlled, open-label, phase 3 trial. Lancet.

Imel, Erik A., et al. "Burosumab Versus Continuation of Conventional Therapy in Children With X-linked Hypophosphatemia: A Randomised, Active-controlled, Open-label, Phase 3 Trial." Lancet 2019.

Imel, Erik A., et al. "Burosumab Versus Continuation of Conventional Therapy in Children With X-linked Hypophosphatemia: A Randomised, Active-controlled, Open-label, Phase 3 Trial." Lancet 2019.